Seres Therapeutics, Inc.

As of June 30, 2026, Seres Therapeutics Inc carries a market capitalization of 67.12M, placing it among publicly traded companies globally. Its enterprise value stands at 103.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Seres Therapeutics Inc's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Seres Therapeutics Inc has 9.83M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 38.96, and the price-to-book ratio stands at 2.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 62.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 103.05M versus a market cap of 67.12M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Seres Therapeutics Inc maintains a current ratio of 2.11, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Seres Therapeutics Inc posted a negative return on equity (ROE) of -66.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.31, reflecting losses generated across the asset base. The company generates approximately 21,902.86 in revenue per employee across its workforce of 75.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Seres Therapeutics Inc's stock has declined approximately 87.82% over the past 52 weeks. The 50-day moving average sits at 3.46, while the 200-day moving average is 6.41.

Over the twelve months ended June 30, 2026, Seres Therapeutics Inc generated 1.65M in revenue and converted that into -19.66M in net income, yielding earnings per share of -2.09. EBITDA reached -70.54M, while operating income came in at -68.47M.

As of June 30, 2026, Seres Therapeutics Inc holds 13.65M in cash and equivalents against 49.58M in total debt, resulting in a net debt position of -13.65M. Total book value stands at 30.23M, with working capital of 19.53M providing operational flexibility.

Seres Therapeutics Inc produced -44.87M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -32,386.10 in capital expenditures, free cash flow totaled -44.90M - equivalent to -4.78 per share.

Over the twelve months ended June 30, 2026, Seres Therapeutics Inc posted a gross margin of 29.47, reflecting its pricing power and cost economics. The operating margin of -4,154.38 and net profit margin of -1,192.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -69.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.38, meaning Seres Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Seres Therapeutics Inc's most recent stock split took place on April 22, 2025 with a 20:1 split ratio.

As of June 30, 2026, Seres Therapeutics Inc has an Altman Z-Score of -15.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.